Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics
- Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch
- Proceeds will be used to develop next-generation T-cell receptor-based therapies for cancer treatment
- TCR therapy pioneer and industry veteran Dr Bent Jakobsen appointed as Chairman of the Board
Basel, Switzerland, May 3, 2022. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the completion of a CHF 15.5 million (EUR 15.2 m / USD 16.7 m) seed financing round, co-led by Pureos Bioventures and Novo Holdings.
